Roivant Sciences ( (ROIV) ) has shared an update.
Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio with the innovative VTAMA® cream for treating plaque psoriasis. This strategic move enhances Organon’s capabilities in providing nonbiologic, non-steroidal topical treatments, potentially addressing atopic dermatitis in the future. With this acquisition, Organon aims to leverage its global reach to maximize VTAMA’s impact on patients worldwide, while continuing to advance its mission to improve healthcare solutions.
For detailed information about ROIV stock, go to TipRanks’ Stock Analysis page.
